Trials / Enrolling By Invitation
Enrolling By InvitationNCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 752 (estimated)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 55 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACP-204 | ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule |
Timeline
- Start date
- 2024-04-23
- Primary completion
- 2029-04-01
- Completion
- 2029-05-01
- First posted
- 2024-01-08
- Last updated
- 2026-04-07
Locations
69 sites across 12 countries: United States, Brazil, Bulgaria, Chile, Czechia, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06194799. Inclusion in this directory is not an endorsement.